Understanding Dementia

Dementia isn’t a single disease but an umbrella term for a decline in memory, thinking, and reasoning severe enough to interfere with daily life. Alzheimer’s disease is the most common cause, accounting for the majority of cases, but other forms include vascular dementia (caused by reduced blood flow to the brain), Lewy body dementia, and frontotemporal dementia. Because the underlying causes differ, treatment is tailored to the specific type of dementia, its stage, and the symptoms a person is experiencing. Getting an accurate diagnosis of the specific subtype from the best neurologist available is the foundation for choosing the right treatment path.

Non-Pharmacological Approaches

Before or alongside medication, non-drug strategies play a central role in dementia care. Cognitive training and structured mental stimulation can help some patients maintain function longer, while physical exercise has consistently been linked to slower cognitive decline and better overall wellbeing. Structured daily routines, social engagement, and a safe, familiar home environment help reduce confusion and agitation. Diet and cardiovascular health management controlling blood pressure, cholesterol, and blood sugar are also considered important, particularly for vascular dementia, where protecting blood flow to the brain is central to slowing progression. Because these approaches carry few risks and can meaningfully improve quality of life, they’re recommended as part of nearly every dementia care plan, regardless of stage.

Pharmacological Treatments

For decades, the mainstay drug treatments for dementia have targeted symptoms rather than the underlying disease process, and prescribing decisions are typically best made in consultation with a multispeciality hospital team, since dosing and combinations often depend on a patient’s broader health picture:

Cholinesterase inhibitors (donepezil, rivastigmine, galantamine) help boost levels of a brain chemical involved in memory and are commonly used for mild to moderate Alzheimer’s disease.
Memantine works through a different mechanism and is often used for moderate to severe Alzheimer’s, sometimes in combination with a cholinesterase inhibitor.
Medications for behavioral symptoms, such as agitation, depression, or sleep disturbances, may be added carefully, since older adults with dementia are more sensitive to side effects from psychiatric medications.

These drugs can ease symptoms and, for some patients, modestly slow functional decline, but they do not stop the disease from progressing.

A New Generation of Disease-Modifying Drugs

The most significant shift in dementia treatment in recent years has been the emergence of drugs designed to act on the underlying biology of Alzheimer’s disease rather than just its symptoms. Anti-amyloid monoclonal antibodies lecanemab (Leqembi) and donanemab (Kisunla) work by clearing amyloid plaques, a hallmark protein buildup associated with Alzheimer’s, from the brain. Clinical trials have shown these drugs can meaningfully slow the pace of cognitive decline in people with early-stage disease, marking the first treatments able to influence the disease process itself rather than only manage symptoms.

Access to these therapies has been improving as well. An at-home injectable version of lecanemab has been approved, allowing patients already on the drug to self-administer it rather than requiring in-clinic IV infusions, a change that can meaningfully ease the burden on patients and caregivers. Regulators are also considering whether to extend at-home dosing to the initial treatment phase. Meanwhile, next-generation amyloid-targeting drugs, including trontinemab, are moving through late-stage clinical trials, and researchers are also developing therapies aimed at tau, a second protein implicated in Alzheimer’s progression.

It’s worth being clear-eyed about what these drugs do and don’t do: they are not cures, and they carry real risks, including brain swelling or bleeding that requires monitoring with periodic MRI scans. They are also currently approved specifically for early-stage Alzheimer’s disease with confirmed amyloid pathology, not for dementia in general.

Managing Difficult Symptoms

As dementia progresses, many patients develop agitation, aggression, or distress symptoms that are often harder on patients and caregivers than memory loss itself. Managing these symptoms safely has been an active area of research and drug development. New non-opioid, non-antipsychotic medications targeting agitation specifically related to Alzheimer’s are moving through regulatory review, and early-phase trials have also explored other approaches, including a cannabis-derived compound that showed promise in reducing agitation in people with advanced dementia. These developments matter because current options for behavioral symptoms are limited and can carry significant side effects, especially antipsychotic medications, which are generally used cautiously and only when other approaches haven’t worked.

Device-Based and Investigational Approaches

Beyond drugs, researchers are exploring non-invasive device-based therapies. Sensory stimulation approaches, such as headsets that use specific patterns of light and sound to stimulate brain activity, are being studied as a way to slow early Alzheimer’s disease. Focused ultrasound and other forms of brain stimulation are also under investigation. These approaches remain experimental but reflect a broader push to find safer, more accessible alternatives or complements to infusion-based drug therapy.

The Role of Early and Accurate Diagnosis

Advances in diagnosis have gone hand in hand with new treatment options. Blood tests for Alzheimer’s-related biomarkers are increasingly able to help primary care doctors, not just specialists, identify the disease earlier and more accurately, though confirming a diagnosis and mapping out a treatment plan is still best done with a neurologist. Since the new disease-modifying drugs work best when started early, timely and accurate diagnosis has become more clinically important than ever. A patient benefits far less from an amyloid-clearing drug if the disease has already progressed to a later stage. This is one of the reasons dementia diagnosis and treatment planning increasingly involve a multispeciality hospital setting, where neurologists, geriatricians, radiologists, and other specialists can coordinate testing and treatment decisions together.

Prevention and Risk Reduction

While no treatment can guarantee prevention, research continues to support the idea that certain lifestyle factors can meaningfully reduce dementia risk or delay its onset, including regular physical activity, cardiovascular risk management, social engagement, cognitive stimulation, and treating hearing loss. Large-scale trials are now testing whether combining structured lifestyle interventions with newer drug classes, such as GLP-1 medications originally developed for diabetes and weight management, can further reduce risk, an approach being studied in global research initiatives building on earlier lifestyle-intervention trials.

Outlook

Dementia treatment has entered a genuinely new phase. For decades, care was limited to managing symptoms; today, disease-modifying drugs, improved diagnostic tools, and a growing pipeline of new therapies are starting to shift the conversation toward slowing, and eventually perhaps preventing, the disease itself. That said, current treatments still offer modest rather than dramatic benefits, and much of dementia care continues to rely on the fundamentals: an accurate diagnosis, thoughtful symptom management, and consistent support for both patients and the caregivers who look after them.